Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of pegylated liposomal doxorubicin（PLD）plus Albumin-Bound Paclitaxel and trastuzumab as neoadjuvant therapy in HER-2 positive breast cancer.
Breast Cancer
DRUG: Pegylated Liposomal Doxorubicin|DRUG: Albumin-bound paclitaxel|DRUG: Trastuzumab
Pathological complete response(pCR) rate, Percentage of patients who do not exhibit residual invasive breast cancer in breast and lymph nodes at time of surgery, 5 months
Rate of Breast conserving surgery, Percentage of patients undergoing breast-conserving surgery after neoadjuvant therapy, 5 months|Rate of surgery, Percentage of patients undergoing mastectomy and breast-conserving surgery after neoadjuvant therapy, 5 months|adverse events, Incidence and Severity of adverse events ,according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, 5 months
This is a single-center, prospective, single arm phase II study. Eligible patients will receive neoadjuvant therapy with pegylated liposome doxorubicin (PLD)/albumin-bound paclitaxel/trastuzumab regimentation.

This study consists of two phases, the first phase aims to determine the maximum tolerated dose (MTD) of PLD, and the second phase will explore the efficacy and safety of the regimen.